Bayer to acquire exclusive license from Cedilla Therapeutics on selective inhibitors in pre-clinical precision oncology
Exclusive license agreement includes rights to develop and commercialize Cedilla's CyclinE1/CDK2 inhibitors Assets are currently in pre-clinical development with potential to serve patients